There is clinical evidence that AAT slows or perhaps even stops the pancreatic inflammatory beta cells. Recent research indicates highly favorable results in animal models treated with AAT.

Kamada reported positive results for efficacy and safety in a unique of its kind, phase 1/2  clinical study in pediatric and young adult patients suffering from Type-1 Diabetes (T1D). The patients were treated with Kamada’s Glassia product that contains the AAT protein and that was fully developed by Kamada.

Analysis of the study data shows that AAT may slow down the rate of disease progression by allowing continued functionality of insulin-secreting beta cells and better glycemic control. This effect may potentially reduce future severe disease complications.

Kamada is currentrly conducting a Phase 2/3 clinical trial of Glassia® to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).This trial will evaluate the safety and efficacy of intravenous Glassia to halt disease progression and maintain the ability of the pancreas to produce insulin.  By maintaining its ability to produce insulin, the body can independently control glucose level and avoid diabetes complications that result from poor glycemic control (e.g., cardiovascular disease, kidney disease, eye and vision problems, neurological damage and more).